BioNTech SE Sponsored ADR $BNTX Shares Newly Bought by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) during the 3rd quarter, HoldingsChannel reports. The institutional investor acquired 6,249 shares of the company’s stock, valued at approximately $614,000.

Other institutional investors also recently bought and sold shares of the company. Integrated Wealth Concepts LLC acquired a new stake in BioNTech in the 2nd quarter worth approximately $39,000. Farther Finance Advisors LLC increased its stake in BioNTech by 31.5% during the 3rd quarter. Farther Finance Advisors LLC now owns 493 shares of the company’s stock valued at $48,000 after purchasing an additional 118 shares in the last quarter. Quintet Private Bank Europe S.A. increased its stake in BioNTech by 232.8% during the 3rd quarter. Quintet Private Bank Europe S.A. now owns 1,917 shares of the company’s stock valued at $188,000 after purchasing an additional 1,341 shares in the last quarter. Sei Investments Co. purchased a new position in shares of BioNTech in the first quarter worth $220,000. Finally, Vise Technologies Inc. purchased a new position in shares of BioNTech in the third quarter worth $228,000. 15.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on BNTX shares. Morgan Stanley dropped their price objective on shares of BioNTech from $114.00 to $106.00 and set an “overweight” rating on the stock in a report on Wednesday, November 4th. Berenberg Bank set a $140.00 target price on BioNTech in a research report on Wednesday, September 16th. UBS Group reduced their target price on BioNTech from $135.00 to $125.00 and set a “buy” rating for the company in a research note on Wednesday, November 4th. Wall Street Zen raised BioNTech from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of BioNTech in a research note on Friday, October 2nd. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $123.60.

Insider Activity at BioNTech

In other news, CEO Ugur Sahin sold 36,209 shares of the company’s stock in a transaction on Friday, October 9th. The shares were sold at an average price of $95.37, for a total value of $3,453,252.33. Following the sale, the chief executive officer directly owned 36,209 shares of the company’s stock, valued at $3,453,252.33. This represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 807,209 shares of company stock valued at $79,246,837. 19.20% of the stock is owned by corporate insiders.

BioNTech Stock Performance

BNTX opened at $87.51 on Monday. BioNTech SE Sponsored ADR has a 12-month low of $79.52 and a 12-month high of $124.00. The company has a current ratio of 8.55, a quick ratio of 8.52 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $22.13 billion, a PE ratio of -12.78 and a beta of 1.28. The firm has a 50 day moving average of $94.66 and a two-hundred day moving average of $96.70.

BioNTech Profile

BioNTech SE is a biotechnology company based in Mainz, Germany. Founded in 2008, it develops medicines and vaccines, with a focus on immunotherapies for cancer and infectious diseases.

The company’s research uses technologies including messenger RNA (mRNA), antibodies, and cell-based therapies. Its best-known product is Comirnaty, an mRNA vaccine against COVID-19 developed and commercialized in partnership with Pfizer. BioNTech also has a broad oncology research and development portfolio.

BioNTech works with partners to develop and distribute products internationally.